The legacy of the Theranos debacle weighs especially heavy on women in biotech

The trial of Elizabeth Holmes, former CEO and founder of the blood test company Theranos, is set to begin next week. Holmes is charged with wire fraud, having allegedly defrauded investors about the accuracy of Theranos’ technology. She’s pleaded not guilty. Many other women founders — especially in biotech and health care — have been getting compared to Holmes. Marketplace’s Jed Kim speaks with Erin Griffith, a reporter who covers startups and venture capital for The New York Times. Griffith says investors often ask female entrepreneurs to prove they’re not another Theranos.